WO1999018210A3 - Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer - Google Patents

Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer Download PDF

Info

Publication number
WO1999018210A3
WO1999018210A3 PCT/US1998/021166 US9821166W WO9918210A3 WO 1999018210 A3 WO1999018210 A3 WO 1999018210A3 US 9821166 W US9821166 W US 9821166W WO 9918210 A3 WO9918210 A3 WO 9918210A3
Authority
WO
WIPO (PCT)
Prior art keywords
prostate cancer
polypeptides
compounds
immunotherapy
methods
Prior art date
Application number
PCT/US1998/021166
Other languages
French (fr)
Other versions
WO1999018210A2 (en
Inventor
Steven G Reed
Davin C Dillon
Daniel R Twardzik
Jennifer L Mitcham
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/946,026 external-priority patent/US6034218A/en
Application filed by Corixa Corp filed Critical Corixa Corp
Priority to AU96893/98A priority Critical patent/AU9689398A/en
Publication of WO1999018210A2 publication Critical patent/WO1999018210A2/en
Publication of WO1999018210A3 publication Critical patent/WO1999018210A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compounds and methods for treating and diagnosing prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides or DNA molecules encoding such polypeptides are also provided. The inventive polypeptides may also be used to generate antibodies useful for the diagnosis and monitoring of prostate cancer. Nucleic acid sequences for preparing probes, primers, and polypeptides are also provided.
PCT/US1998/021166 1997-10-07 1998-10-07 Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer WO1999018210A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU96893/98A AU9689398A (en) 1997-10-07 1998-10-07 Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/946,026 US6034218A (en) 1996-03-15 1997-10-07 Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US08/946,026 1997-10-07
US10267998A 1998-06-23 1998-06-23
US09/102,679 1998-06-23

Publications (2)

Publication Number Publication Date
WO1999018210A2 WO1999018210A2 (en) 1999-04-15
WO1999018210A3 true WO1999018210A3 (en) 1999-08-05

Family

ID=26799614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/021166 WO1999018210A2 (en) 1997-10-07 1998-10-07 Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer

Country Status (2)

Country Link
AU (1) AU9689398A (en)
WO (1) WO1999018210A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343912A2 (en) 2000-11-28 2003-09-17 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
CA2429722A1 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP1402031A2 (en) 2001-06-21 2004-03-31 Isis Innovation Limited Atopy
EP2320235A1 (en) * 2009-11-06 2011-05-11 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker for prostate cancer diagnosis
EP2320234A1 (en) 2009-11-06 2011-05-11 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker combination for prostate cancer diagnosis
EP2700949A1 (en) 2012-08-24 2014-02-26 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Use of biliverdin reductase proteins as cancer marker
CA3058263C (en) * 2017-03-30 2023-08-01 Ecs-Progastrin Sa Compositions and methods for detecting prostate cancer
CN111133104A (en) * 2017-08-11 2020-05-08 特里比奥迪卡有限责任公司 Methods of generating epitopes that bind to recognition molecules by templated assembly
CN111679074A (en) * 2020-07-11 2020-09-18 成都益安博生物技术有限公司 Prostate cancer peripheral blood TCR marker and detection kit and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033909A2 (en) * 1996-03-15 1997-09-18 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033909A2 (en) * 1996-03-15 1997-09-18 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN E ET AL.: "Homo sapiens Chromosome X clone bWXD178 (accession number AC004409)", EMBL DATABASE, 16 March 1998 (1998-03-16), Heidelberg, Germany, XP002094679 *
HAWKINS T L ET AL.: "Genomic sequence from Human 13 (accession number AC000403)", EMBL DATABASE, 9 April 1997 (1997-04-09), Heidelberg, Germany, XP002094678 *

Also Published As

Publication number Publication date
AU9689398A (en) 1999-04-27
WO1999018210A2 (en) 1999-04-15

Similar Documents

Publication Publication Date Title
WO1997033909A3 (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
WO1998037418A3 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO1999047674A3 (en) Compounds and methods for therapy and diagnosis of lung cancer
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1998053076A3 (en) Compounds for diagnosis of tuberculosis and methods for their use
EA200101037A1 (en) CONNECTIONS AND METHODS FOR THE TREATMENT AND DIAGNOSTICS OF LUNG CANCER
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO1998035693A3 (en) Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease
EP1690873A3 (en) Composition and methods for the diagnosis of tumours
ES2133813T3 (en) LAMININE CHAINS: DIAGNOSIS AND THERAPEUTIC USE.
CA2295999A1 (en) Nik proteins, nucleic acids and methods
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
WO1998016645A3 (en) Compounds and methods for diagnosis of tuberculosis
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
WO1996040039A3 (en) Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof
WO1997008318A3 (en) Compounds and methods for treatment and diagnosis of prostate cancer
WO1998021343A8 (en) Genes encoding telomerase proteins
WO1997008314A3 (en) Telomere repeat binding factor and diagnostic and therapeutic use thereof
AU2740100A (en) A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
EP0825260A3 (en) Arginase II
WO1999067382A3 (en) Angiopoietin-like growth factor sequences
WO1999018210A3 (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
WO2001018046A3 (en) Ovarian tumor sequences and methods of use therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA